SAGE Therapeutics (SAGE) Misses Q3 EPS by 5c
Tweet
Share
E-mail
Get Alerts SAGE Hot Sheet
Join SI Premium – FREE
SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($1.15), $0.05 worse than the analyst estimate of ($1.10).
For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ABM Industries (ABM) Misses Q2 EPS by 2c ; Offers Guidance
- Deutsche Bank maps out volatile ‘1999 meets 1990’ macro outlook for investors
- Pfizer reports phase 2b results for monthly obesity drug berobenatide
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
